Viridian Therapeutics, Inc\de 10-Q quarterly reports

Viridian Therapeutics announced its Q2 2026 financial results, highlighting the FDA approval of veligrotug (Lumvoa) for thyroid eye disease and positive clinical trial data for elegrobart, while also reporting significant operating losses.

Viridian Therapeutics, Inc. reported a net loss of $104.9 million for the first quarter ended March 31, 2026, with cash, cash equivalents, and marketable securities totaling $762.2 million.

Viridian Therapeutics reports a $70 million license revenue, significant progress in its veligrotug and VRDN-003 TED programs, and expanded FcRn inhibitor pipeline, alongside increased operating losses.

Viridian Therapeutics reports significant clinical progress for its TED and FcRn programs, including positive Phase 3 data for veligrotug and a $70 million upfront payment from a new Japan licensing agreement.

Viridian Therapeutics reports a net loss for Q1 2025 and provides updates on its thyroid eye disease (TED) and FcRn inhibitor programs, anticipating key data readouts and regulatory submissions.

Viridian Therapeutics reports a net loss of $76.7 million for the third quarter of 2024, while highlighting progress in its clinical programs for thyroid eye disease and FcRn inhibitors.

Viridian Therapeutics reports a net loss of $65 million for the second quarter of 2024, while advancing its clinical programs for thyroid eye disease and other autoimmune disorders.

Viridian Therapeutics reports a net loss of $48.5 million for the first quarter of 2024, while highlighting progress in its clinical programs and a strong cash position.